A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1194-1203

  Simpson, George M ^a   Mahmoud, Ramy A ^b   Lasser, Robert A ^c   Kujawa, Mary ^b   Bossie, Cynthia A ^b   Turkoz, Ibrahim ^b   Rodriguez, Steven ^b   Gharabawi, Georges M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CANNABIS; CHLORPROMAZINE; COCAINE; DIAMORPHINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LONG ACTING DRUG; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; HEADACHE; HOSPITAL READMISSION; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; SYMPTOMATOLOGY;

EID: 33748985146     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0804     Document Type: Article

References (29)

1. Csemansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
2. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980;37:16-24
3. Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025-1029
4. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002;159:554-560
5. Arato M, O'Connor R, Meltzer HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-215
6. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-2702
7. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206
8. Docherty JP, Grogg AL, Kozma C, et al. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Presented at the 41st annual meeting of The American College of Neuropsychopharmacology; December 8-12, 2002; San Juan, Puerto Rico
9. Valenstein ML, Copeland A, Owen R, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-639
10. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699
11. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891
12. Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59 (suppl 8):S10-S15
13. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
14. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257
15. Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
16. Lasser R, Bossie CA, Gharabawi G, et al. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004;83:263-275
17. Lindenmayer J-P, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-1089
18. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
20. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546
21. Cramer JA, Rosenheck R, Kustra P. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull 2000;26:659-666
22. Strauss JS, Carpenter WT Jr. Prediction of outcome in schizophrenia, 3: five-year outcome and its predictors. Arch Gen Psychiatry 1977;34:159-163
23. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-329
24. Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000;177:42-46
25. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233
26. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-1222
27. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999;156:412-418
28. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
29. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-130